Tenaya Therapeutics (NASDAQ:TNYA) Issues Quarterly Earnings Results

Tenaya Therapeutics (NASDAQ:TNYA) released its quarterly earnings data on Wednesday. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.02, FiscalAI reports. The company had revenue of $1.70 million during the quarter, compared to analysts’ expectations of $0.80 million.

Tenaya Therapeutics Price Performance

Tenaya Therapeutics stock traded up $0.01 during trading hours on Wednesday, reaching $0.37. The stock had a trading volume of 1,602,720 shares, compared to its average volume of 3,456,521. The stock has a market cap of $84.31 million, a PE ratio of -0.70 and a beta of 2.88. Tenaya Therapeutics has a 52 week low of $0.35 and a 52 week high of $1.56. The company has a fifty day simple moving average of $0.56 and a 200-day simple moving average of $0.71.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on TNYA. Weiss Ratings restated a “sell (d-)” rating on shares of Tenaya Therapeutics in a research report on Monday, October 26th. Wall Street Zen upgraded Tenaya Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, September 6th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Tenaya Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $4.00.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for genetic and other serious diseases of the heart. The company combines gene therapy, gene editing, cell therapy and small-molecule drug discovery technologies to target the underlying causes of cardiovascular disease rather than treating symptoms alone.

Tenaya’s pipeline has included TN-201, an adeno-associated virus gene replacement therapy being developed for patients with MYBPC3-associated hypertrophic cardiomyopathy, and TN-401, a gene therapy candidate designed for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.